ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0524

Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors

Esra Erpek1, Hasan Kocaayan2, Elif Ediboğlu3, Ayberk Sinci4, Özgür Tosun4, Dilek Solmaz3 and Servet Akar5, 1İzmir Katip Çelebi Üniversitesi, Romatoloji Bilim Dalı, İzmir, Izmir, Turkey, 2Izmir Katip Çelebi University School of Medicine, Rheumatology, Turkey, İzmir, Turkey, 3Izmir Katip Çelebi University School of Medicine, Rheumatology, Turkey, İzmir, Izmir, Turkey, 4İzmir Katip Çelebi Üniversitesi, Radyoloji Bilim Dalı, İzmir, Izmir, Turkey, 5Department of Medicine, Izmir Katip Çelebi University School of Medicine, Izmir, Turkey

Meeting: ACR Convergence 2025

Keywords: Ankylosing spondylitis (AS), radiography, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: This study aimed to assess the rate of progression in sacroiliac joints in non-radiographic axial spondyloarthritis (nr-axSpA) and to identify the predictive factors for the progression.

Methods: In total 321 patients classified as nr-axSpA and who had at least one follow-up pelvic radiograph among 695 patients followed in an axSpA cohort were included in the present analysis. A total of 647 radiographs were evaluated by two independent readers (blinded for the chronological order) according to the modified New York criteria. Discrepancies were resolved by a third experienced rheumatologist. Progression rates from nr-axSpA to r-axSpA and the related factors were assessed over a follow-up period of two and five years. Potential factors influencing progression to r-axSpA at the five-year follow-up were tested by using the Generalized Estimating Equations (GEE) method. Factors/covariates has a significance level of < 0.10 were included in the multivariate analysis.

Results: Of the 321 nr-axSpA patients followed in the axSpA cohort, 194 had radiographic follow-up at two years and 116 at five years. At two years follow up progression to r-axSpA was observed in 17.5% of patients at and at five years in 24.1%. In univariate analysis symptom duration, education level, body mass index, Bath Ankylosing Spondylitis Function Index score, score, C-reactive protein levels, Bath Ankylosing Spondylitis Metrology index scores and the presence of family history for SpA according to ASAS proposal were found to be associated with the radiographic progression. However in multivariate model only elevated C-reactive proteine and body mass index were identified as significant predictors of progression to r-axSpA (Table 2).

Conclusion: In our study, the 5 year progression rate from nr-axSpA to r-axSpA was 24.1%. Previous studies have reported progression rates ranging from 2% to 43.5%, depending on variations in patient selection, imaging frequency, and disease duration at diagnosis (1). The recently published PROOF study, which included axSpA patients who were diagnosed within 1 year, reported a 5-year progression rate of 16% (2). The relatively higher rate observed in our cohort may be attributed to the longer symptom duration Importantly, among the factors analyzed, body mass index (BMI) emerged as a significant predictor of radiographic progression, which has not been consistently emphasized in previous studies. Serum CRP levels was also associated with progression, in line with established risk factors. The identification of BMI as a significant factor in our cohort highlights the potential role of metabolic and mechanical stress in disease progression and warrants further investigation. Our results reinforce the importance of integrating clinical, laboratory, and imaging parameters to improve prediction of progression in nr-AxSpA.References1-Protopopov M, Poddubnyy D. Radiographic progression in non-radiographic axial spondyloarthritis. Expert Rev Clin Immunol. 2018 Jun;14(6):525-533.2-Poddubnyy D. et al. Radiographic Progression in Sacroiliac Joints in Patients With Axial Spondyloarthritis: Results From a Five-Year International Observational Study. A)CR Open Rheumatol. 2024 Feb;6(2):103-110.

Supporting image 1Table 1: Baseline demographic, disease related clinical, and laboratory characteristics of non-radiographic axSpA patients

Supporting image 2Table 2: Univariable and multivariable longitudinal analysis results of factors influencing progression from nr-axSpA to r-axSpA


Disclosures: E. Erpek: None; H. Kocaayan: None; E. Ediboğlu: None; A. Sinci: None; Ö. Tosun: None; D. Solmaz: None; S. Akar: None.

To cite this abstract in AMA style:

Erpek E, Kocaayan H, Ediboğlu E, Sinci A, Tosun Ö, Solmaz D, Akar S. Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/radiographic-progression-in-sacroiliac-joints-in-five-years-follow-up-in-non-radiographic-axial-spondyloarthritis-patients-and-the-predictive-factors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/radiographic-progression-in-sacroiliac-joints-in-five-years-follow-up-in-non-radiographic-axial-spondyloarthritis-patients-and-the-predictive-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology